Proceed to the Sina Finance APP and search for [Disclosure] to view more evaluation ratings. Investors who have suffered losses can register their claims against the company on the Sina Investor Rights Protection platform. Follow @Sina Securities on Weibo, follow Sina Brokerage Fund on WeChat, search for Sina Investor Rights Protection on Baidu, visit the Sina Finance client, or check the Sina Finance homepage to find us.

The investor rights protection case represented by attorney Liu Peng of Shanghai Huzi Law Firm was recently filed with the court and is still accepting registrations from affected investors. Looking back at the case, on August 16, 2025, Xiangxue Pharmaceutical received the "Administrative Penalty Decision" formally issued by the Guangdong Regulatory Bureau. Due to related-party fund occupation and financial造假 that lasted for five years, the company and relevant responsible persons were collectively fined 20.65 million yuan. Based on current relevant laws and regulations, investors who fall within the following two periods are preliminarily eligible to register for claims: (1) Those who purchased shares between May 20, 2020, and April 29, 2024, and sold them after April 30, 2024, or continued to hold them and incurred losses; (2) Those who purchased shares between March 25, 2017, and September 30, 2024 (inclusive), and sold them after October 1, 2024, or continued to hold them and incurred losses.

Specifically, Xiangxue Pharmaceutical's alleged violations of information disclosure regulations primarily involve false records and major omissions in its annual reports. Among these, in December 2019, five villas owned by Xiangxue Pharmaceutical on Guangzhou Bio-Island were demolished by relevant government departments. The company failed to properly account for the losses from the demolished villas as construction-in-progress, resulting in its 2019 annual report overstating profits by 53.8325 million yuan, which constituted 45.98% of the total profit disclosed for that period. The 2019 annual report contained false records. It was not until April 30, 2024, that Xiangxue Pharmaceutical issued an announcement adjusting the relevant construction-in-progress costs. Furthermore, due to the failure to disclose non-operating fund occupation by related parties as required, Xiangxue Pharmaceutical's annual reports from 2016 to 2020 contained major omissions, primarily involving the company's controlling shareholder, Guangzhou Kunlun Investment Co., Ltd., among others. The illegal occupation of the listed company's funds by its related parties has already been severely punished by regulators. In the subsequent investor compensation lawsuits, the penalty decision will also serve as strong supporting evidence.

(This article was contributed by Attorney Liu Peng of Shanghai Huzi Law Firm and does not represent the views of Sina Finance. Attorney Liu Peng, with 19 years of focus on securities rights protection, has successfully represented small and medium investors of over 300 listed companies, including China Youth Media, Guohua Network Security, and Jinjia Holdings, since commencing practice in 2006. With over 14,000 cases currently being handled and a success rate of 99.2%, Attorney Liu Peng, as a seasoned securities rights protection lawyer, accurately pinpoints the core of cases, possesses extensive litigation experience, and employs efficient claim strategies to secure maximum benefits for investors, leading the industry in rights protection capabilities. Choosing the right lawyer is crucial for securities rights protection! Professionalism determines the odds of success, experience ensures outcomes; selecting Attorney Liu Peng makes your claim process more secure and efficient!)

For a wealth of information and precise analysis, all available on the Sina Finance APP.